Rheumatology Therapeutics Market Report 2025 (Global Edition)

Global Rheumatology Therapeutics Market Report 2025 Market Size Split by Drug Class (Disease Modifying Anti-Rheumatic Drugs (DMARDs), Synthetic Disease Modifying Anti-Rheumatic Drugs, Biologic Disease...

Rheumatology Therapeutics Market Report Description

We have various report editions of Rheumatology Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape: The Rheumatology Therapeutics Market

Large industry players are heavily investing in R&D to support their product lines, which will spur further growth in the rheumatology market. Aside from major product launches, recurring alliances, mergers and acquisitions, large investments, and cooperation with other organizations, market participants are also strategically expanding their businesses globally. To survive and grow in a market that is becoming more and more competitive, rivals in the rheumatology sector must provide affordable medications.
For instance, in October 2023, Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ) in individuals living with systemic lupus erythematosus (SLE)
Source:(https://www.prnewswire.com/news-releases/lupus-therapeutics-partners-with-abbvie-on-clinical-trial-recruitment-efforts-in-sle-through-lucin-lupus-clinical-trial-network-301964999.html)

Top Companies Market Share in Rheumatology Therapeutics Industry: (In no particular order of Rank)

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb
• Celgene Corporation
• Eli Lilly and Company
• Gilead Sciences
• Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co.
• Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Inc.
• Roche Holding AG
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• UCB S.A.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of The Rheumatology Therapeutics Market

Which Region Will Dominate the Market in 2024?

According to Cognitive Research, the North American region dominated the market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. North America is expected to hold a dominant share in the rheumatology therapeutics market over the forecast period. The market growth of the rheumatology therapeutics in the region is anticipated to be driven by the increasing prevalence of rheumatic diseases, the robust position of major players in the industry, the increasing introduction of novel therapies like monoclonal antibodies for rheumatic disease, and the growing investments made by industry participants in research to develop new treatments and biosimilars for this illness.
For instance, according to the Centers for Disease Control and Prevention (CDC), in October 2021, about 1 in 4 United States adults (23.7%) or about 58.5 million people have doctor-diagnosed arthritis. 
Source:(https://www.cdc.gov/arthritis/data_statistics/national-statistics.html)

For instance, according to the Government of Canada, in September 2020, approximately 374,000 (1.2%) Canadians aged 16 years and older live with diagnosed rheumatoid arthritis. Such a massive prevalence of this disease creates the need for drugs for treatment and thus drives market growth.
Source:(https://www.canada.ca/en/public-health/services/publications/diseases-conditions/rheumatoid-arthritis.html)

In addition, in May 2020, Teva and Celltrion Healthcare launched TRUXIMA (rituximab-abbs) injection for rheumatoid arthritis. It is the biosimilar of Rituxan(rituximab) for this indication in the United States. 
Source:(https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2020/Teva-and-Celltrion-Healthcare-Announce-the-Launch-of-TRUXIMA-rituximab-abbs-Injection-for-Rheumatoid-Arthritis-the-Only-Biosimilar-to-Rituxan-rituximab-Available-in-the-United-States-for-This-Indication/default.aspx)

Moreover, the United States Food and Drug Administration (FDA) approved Voltaren arthritis pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as an over-the-counter (OTC) product for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults (18 years and older).
Source:(https://us.gsk.com/en-us/media/press-releases/fda-approves-gsk-s-voltaren-arthritis-pain-for-over-the-counter-use-in-the-united-states/)
This will further lead to the growing adoption of rheumatoid arthritis drugs in the United States, driving the growth of the rheumatology therapeutics market over the forecast period.
Therefore, during the forecast period, the growth of the rheumatology therapeutics market is increasing due to the above factors.

Which Region Is Expanding at The Fastest CAGR?

The Asia Pacific is projected to grow at a faster rate with a CAGR of XX% during the forecast period between 2024 and 2031. Asia Pacific is expected to grow fastest in the rheumatology therapeutics Market. Asia Pacific is projected to gain tremendous growth in the upcoming years due to the high incidence, rising healthcare costs, population expansion, advances in medicine, regulatory backing, and increasing awareness, the rheumatology therapeutics market in Asia Pacific is growing. It is anticipated to increase significantly due to aging populations and innovative treatment developments in nations like China, Japan, and India. Research is an investment made by pharmaceutical companies. 
For instance, according to a study published by The Lancet in September 2023, globally, 595 million people had osteoarthritis in 2020, with the Asia Pacific region accounting for a prevalence of 8632.7 per 100,000. Such high figures indicate an increasing demand for rheumatology therapeutics in the region.
Source:(https://pubmed.ncbi.nlm.nih.gov/37675071/)

For instance, in July 2023, Biocon Biologics Ltd., a subsidiary of Biocon Ltd, announced the availability of HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), in the U.S. for the treatment of rheumatoid arthritis
Source:(https://www.biocon.com/after-five-years-of-successful-experience-internationally-biocon-biologics-hulio-biosimilar-to-humira-now-available-in-the-united-states/)
 

The current report Scope analyzes Rheumatology Therapeutics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Rheumatology Therapeutics Market Analysis

Segment Performance in The Rheumatology Therapeutics Market

Drug Class  Segment Analysis

The nonsteroidal anti-inflammatory drugs (NSAIDs) segment is dominating the rheumatology market due to the increasing need for nonsteroidal anti-inflammatory drugs (NSAIDs) for the symptomatic treatment of RA diseases based on the manifestation of acute pain and persistent musculoskeletal symptoms, the market is expected to grow. The desire for better patient outcomes, illness management, and focused therapy development is what fuels the need. This partnership between Rheumatoid Arthritis Therapeutics and pharmaceutical companies highlights a common dedication to meeting patients' changing demands. Many people use nonsteroidal anti-inflammatory drugs (NSAIDs) to treat the symptoms of rheumatic diseases. NSAIDs are used to treat diseases like inflammation and provide patients with symptomatic relief. 
For instance, according to the study published in Frontiers in Immunology, titled "Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis" in July 2021, nonsteroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylate, naproxen, ibuprofen, and etodolac, are used to alleviate pain, swelling, and inflammation and are used as the first line treatment for rheumatoid arthritis. This has accelerated the expansion of the market sector and led to a greater use of NSAIDs in the treatment of RA. 
Source:(https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.686155/full#:~:text=Some%20of%20these%20agents%20have,%2C%20swelling%2C%20and%20decrease%20inflammation.)
Furthermore, the increasing use of NSAIDs to treat rheumatoid arthritis is anticipated to fuel the segment's expansion. 
For instance, in August 2021, Alkem Laboratories launched ibuprofen and famotidine tablets to relieve rheumatoid arthritis and osteoarthritis symptoms in the United States.
Source:(https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/alkem-laboratories-launches-ibuprofen-famotidine-tablets-in-us-market/articleshow/85029512.cms)

For instance, in September 2021, Lupin launched generic Duexis (ibuprofen and famotidine) tablets used to treat the symptoms of rheumatoid arthritis and osteoarthritis in the United States market.
Source:(https://www.lupin.com/lupin-launches-authorized-generic-version-of-duexis-in-the-united-states/)
As a result, growth in the NSAIDS segment is anticipated throughout the projection period due to the above factors. 
 

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Rheumatology Therapeutics Industry. Request a Free Sample PDF!

Disease Indication Segment Analysis

The rheumatoid arthritis segment is anticipated to dominate the market of rheumatology. The dominance of the rheumatoid arthritis segment in the rheumatology market can be attributed to several factors. Rheumatoid arthritis is one of the most prevalent autoimmune diseases globally, affecting millions of people and leading to significant morbidity and disability. Advancements in research and technology have led to the development of targeted biological therapies and disease-modifying drugs specifically tailored for rheumatoid arthritis, enhancing treatment efficacy and patient outcomes. Additionally, the rising awareness about early diagnosis and proactive management of rheumatoid arthritis has fueled market growth, with a focus on improving quality of life and reducing long-term complications for affected individuals. These factors collectively contribute to the prominence of the rheumatoid arthritis segment within the rheumatology market.
For instance, according to the study published in Rheumatology International, titled "The global prevalence of rheumatoid arthritis (RA): a meta-analysis based on a systematic review" in November 2020, the global prevalence of RA was estimated to be 0.46 percent. Due to this, RA treatment methods will be used more frequently, which will fuel market expansion. 
Source:(https://pubmed.ncbi.nlm.nih.gov/33175207/#:~:text=The%20global%20RA%20prevalence%20estimate,%25)%20from%201955%20to%202015.)
Additionally, rising product launches by the market players are expected to boost the market's growth. 
For instance, in September 2020, Lupin launched generic leflunomide in the United States to treat adults with active rheumatoid arthritis.
Source:(https://www.lupin.com/lupin-launches-leflunomide-tablets-usp/)
As a result, patients would use rheumatoid treatments more frequently, propelling the market's expansion. In addition, the market is growing as more biosimilars are approved to treat rheumatoid arthritis. 
For instance, in October 2021, the United States Food and Drug Administration approved Cyltezo. It is one of the first rheumatoid arthritis biosimilars that can be used in place of Humira.
Source:(https://www.prnewswire.com/news-releases/us-fda-approves-boehringer-ingelheims-high-concentration-citrate-free-formulation-of-cyltezo-adalimumab-adbm-injection-302132457.html)
 

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Rheumatology Therapeutics Route of Administration Segment Analysis

Route of Administration Segment Analysis

Based on route of administration, the parenteral route segment held the market with the largest revenue share of XX% in 2023 and is expected to grow at a CAGR of XX% over the forecast period 2024-2031, due to its better pharmacokinetics and pharmacodynamics, simpler administration, higher predicted growth rate, and efficacy for certain therapies. These components highlight how well-suited it is to provide complex formulas and indicate future market development possibilities. Furthermore, it is expected that the use of placental tissue matrix injections in the treatment of osteoarthritis will rise as proof of their effectiveness accumulates.
For instance, a study published by NCBI in June 2023 showed that the application of PTM injections led to reduced levels of Matrix Metalloproteinase-1 (MMP-1) and increased levels of Interleukin-4 (IL-4) in a rat model of osteoarthritis, indicating the potential of these injections to alleviate symptoms of the condition.
Source:(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316113/)

• Parenteral Route
• Oral Route
• Topical

Rheumatology Therapeutics Distribution Channel Segment Analysis

Distribution Channel Segment Analysis

The online pharmacy segment of the rheumatology market is projected to increase substantially over the forecast period due to the global e-commerce industry growth. In the post-pandemic period, consumers' growing propensity to meet their prescription needs through online pharmacies will serve as the foundation for industry changes. Customers may purchase digitally with the most convenience and a range of medical alternatives to suit their individual needs. The increasing focus of many e-commerce behemoths on capitalizing on continuous digitalization to penetrate the healthcare industry will additionally expedite the dynamics of the market. 
For instance, in April 2022, Walmart-owned Flipkart launched the Flipkart Health Plus app to accommodate more than 500 independent sellers and boost access to drugs.
Source:(https://m.economictimes.com/tech/technology/flipkart-launches-separate-app-for-healthcare-biz-to-take-on-1mg-pharmeasy-others/articleshow/90686472.cms)
 

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Author's Detail

Swasti Dharmadhikari

Research associate at Cognitive Market Research

LinkedIn

Profile

Swasti Dharmadhikari, an agile and achievement-focused market researcher with an innate ardor for deciphering the intricacies of the Service & Software sector. Backed by a profound insight into technology trends and consumer dynamics, she has committed herself to meticulously navigating the ever-evolving terrain of digital Services and software solutions.

Author's Conclusion